Oncology Views & Analysis

Views & Analysis

Janssen CAR-T is Priority Medicine in EU, and more

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.

Views & Analysis

Oncology round-up: Shareholders question BMS/Celgene merger,...

Will it happen or not?

Views & Analysis

Oncology round-up: CAR-T conference raises hopes for solid t...

Kisaco Research’s CAR-T Congress EU could not have come at a better time – the day after it finished NICE announced it had granted funding for a new use for Novartis’ cancer cell therapy Ky

Views & Analysis

2018 in review: Merck & Co sets new standards in oncology, C...

Oncology drugs are developing at a fast pace, but 2018 was the year when immune-oncology set new standards for several of the most common forms of the disease.

Views & Analysis

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

AstraZeneca looks to CRISPR to boost success rates

Between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below an already-low industry standard of 5%.

Views & Analysis